Clinical Trial Update: Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safety and efficacy of PN-152,243 and PN-196,444 in preventing thrombocytopenia in patients with Non-Hodgkin lymphoma and Hodgki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Thrombocytopenia

Drugs mentioned

• PN-152,243
• PN-196,444

Snippet

Sponsor: Pfizer | Conditions: Non-Hodgkin Lymphoma, Hodgkin Disease | Phase 3 | Status: COMPLETED